Breaking Finance News

Zacks Investment Research upgraded Sangamo Biosciences, Inc. (NASDAQ:SGMO) to Hold in a report released today.

Zacks Investment Research has upgraded Sangamo Biosciences, Inc. (NASDAQ:SGMO) to Hold in a report released on 11/30/2016.

Yesterday Sangamo Biosciences, Inc. (NASDAQ:SGMO) traded 0.00% even at $3.25. The company’s 50-day moving average is $3.84 and its 200-day moving average is $5.04. The last stock close price is down -35.49% from the 200-day moving average, compared to the S&P 500 which has decreased -0.03% over the same time. 0 shares of the stock were exchanged, down from an average trading volume of 886,392

See Chart Below

Sangamo Biosciences, Inc. (NASDAQ:SGMO)

Sangamo Biosciences, Inc. has a 52 week low of $3.10 and a 52 week high of $9.91 The company’s market cap is currently $0.

About Sangamo Biosciences, Inc. (NASDAQ:SGMO)

Sangamo Biosciences Inc. is a clinical-stage biopharmaceutical company. The Company is focused on research, development and commercialization of engineered deoxyribonucleic acid (DNA)-binding proteins for therapeutic genome editing and gene regulation. It is engaged in developing zinc finger DNA-binding proteins (ZFP) therapeutics. Its ZFP Therapeutic, SB-728, a ZFP nuclease (ZFN)-modified autologous cell product for the treatment of Human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS), is the therapeutic application of its ZFN genome editing technology and is evaluated in an ongoing Phase II study of ZFN-modified T-cells (SB-728-T-1101, Cohort 3) and a Phase I/II study of modified hematopoietic stem cells (SB-728mR-HSPC) in HIV-infected subjects. It has preclinical programs in hemophilia A and Lysergic acid diethylamide and research stage programs in monogenic diseases, including certain central nervous system disorders and cancer immunotherapy.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.